bioMerieux (OTCMKTS:BMXMF) Shares Up 5.6% – Still a Buy?

bioMerieux (OTCMKTS:BMXMF) shares rose 5.6% during trading on Friday . The stock traded as high as $87.7980 and last traded at $87.7980. 125 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 374 shares. The stock had previously closed at $83.17.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Zacks Research lowered shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Finally, Piper Sandler assumed coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, bioMerieux has an average rating of “Reduce”.

bioMerieux Stock Down 0.8%

The company has a 50-day simple moving average of $80.70 and a 200-day simple moving average of $92.63. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.